Research and Development
At Jazz, what we’re doing today is transforming the future—of our patients’ lives, of our key therapeutic areas and of the impact we have on the world. We seek scientific breakthroughs in neuroscience and oncology that will result in life-changing medicines and redefine possibilities for patients and their families.
Our R&D approach is patient-centric and proven—we find or create the science that patients need. Jazz begins with a complex, unmet patient need—people who are waiting on the first or a better therapeutic option for their condition—and then we find or create the science that delivers it. We harness the collective talents and expertise of our researchers, scientists, chemists, developers and more to advance our fields of study through our own proprietary programs and assets, and through strategic collaborations with leading innovators, researchers and academia.
(Long-acting Erwinia asparaginase)
NRAS and up to 4 others)1
- R/R AML or HMA Failure MDS2
- First-line, fit AML (Phase 1b)
- Low Intensity Therapy for first-line, unfit AML (Phase 1b)
- HR-MDS (EMSCO)4
- Newly diagnosed older adults with HR-AML4
- AML or HR-MDS >60 yrs (AML18)4
- Newly diagnosed adults with standard- and HR-AML (AMLSG)4
- Newly diagnosed <22 yrs with AML (COG)4
Through Jazz’s patented CombiPlex® platform, Jazz is evaluating oncology combinations to support identification of clinical product candidate(s) and is leading a collaborative approach with partners to research and develop new therapies.